Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Biota Pharmaceuticals Inc

+ Add to Watchlist

BOTA:US

2.4000 USD 0.0400 1.64%

As of 20:10:00 ET on 04/17/2015.

Snapshot for Biota Pharmaceuticals Inc (BOTA)

Open: 2.4300 Day's Range: 2.3600 - 2.4440 Volume: 29,215
Previous Close: 2.4400 52wk Range: 2.1000 - 5.9900 1-Yr Rtn: -56.12%

Stock Chart for BOTA

No chart data available.
  • BOTA:US 2.4000
  • 1D
  • 1M
  • 1Y
2.4400
Interactive BOTA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BOTA

Current P/E Ratio (ttm) -
Estimated P/E(06/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.1723
Est. EPS (USD) (06/2015) -
Est. PEG Ratio -
Market Cap (M USD) 84.24
Shares Outstanding (M) 35.10
30 Day Average Volume 83,015
Price/Book (mrq) 1.0224
Price/Sale (ttm) 1.5695
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 6.6480
Dividend Ex-Date 11/09/2012
5 Year Dividend Growth -
Next Earnings Announcement 05/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BOTA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for BOTA

Biota Pharmaceuticals Inc is an anti-infective drug development company with expertise in respiratory diseases, particularly influenza. The Company developed the first neuraminidase inhibitor. Biota's research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections.

Russell H PlumbChairmanPeter AzzarelloChief Accounting Officer
Joseph M PattiPresident/CEO
More Company Profile & Key Executives for BOTA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil